Maru Yoshiro    Department   School of Medicine, School of Medicine    Position   Professor and Division head
Article types	Original article
Language	English
Peer review	Peer reviewed
Title	Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example.
Journal	Formal name：Endocrine, metabolic & immune disorders drug targets Abbreviation：Endocr Metab Immune Disord Drug Targets ISSN code：18715303/22123873
Volume, Issue, Page	15(2),pp.83-87
Author and coauthor	Maru Yoshiro, Tomita Takeshi*, Deguchi Atsuko, Ieguchi Katsuaki, Takita Morichika, Tsukahara Fujiko, Takemura Kazuhiro, Kitao Akio, Gusovsky Fabian
Authorship	Lead author
Publication date	2015
Summary	TLRs are very important players to regulate innate immune responses. TLR4 controls the host defense by sensing an exotic pathogen, such as lipopolysaccharides. At the same time, some endogenous proteins, including HMGB1 and S100A8, could also function to be a ligand to elicit inflammatory reactions. These facts make TLR4 signaling system very complicated. For instance, the application of TLR4 ligands in cancer therapies is desirable for enhancement of anti-tumor immunity in terms of its reparative nature, but undesirable for enhancement of metastatic growth of cancer cells. In this manuscript, in order to make a novel molecular design to disrupt an interaction between TLR4/MD-2 and endogenous ligands, we provide a potential binding style of the TLR4/MD-2 complex with HMGB1 by using their 3D structural data and docking simulations, and also discuss S100A8 binding to TLR4/MD-2.
DOI	10.2174/187153031502150522123746
PMID	26004773